Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit
22. Mai 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
16. Mai 2023 08:00 ET
|
Solid Biosciences Inc.
— Oral presentation highlighting data from multiple animal models demonstrated administration of AVB-202 resulted in frataxin (FXN) expression in cardiac and central nervous system (CNS) tissues with...
Solid Biosciences Provides First Quarter Business Update and Financial Results
11. Mai 2023 07:30 ET
|
Solid Biosciences Inc.
– Company remains on track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) – – Company ends first quarter with...
Solid Biosciences to Present at JMP Securities Life Sciences Conference
08. Mai 2023 16:05 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Participate in Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
21. April 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference
13. April 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass. , April 13, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results
23. März 2023 08:00 ET
|
Solid Biosciences Inc.
- Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement - -...
Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery
21. März 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Present at Barclays Global Healthcare Conference
07. März 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Present at SVB Securities Global Biopharma Conference
08. Februar 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...